Division of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Expert Opin Pharmacother. 2021 Mar;22(4):403-414. doi: 10.1080/14656566.2020.1843635. Epub 2020 Nov 11.
: Oral pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) represent the cornerstones of HIV infection prevention and treatment. However, despite their high efficacy, the need to take daily oral pill(s) negatively impacts long-term patient adherence. In some cases, it can also be associated with drug-drug interactions and adverse gastrointestinal effects, as well as being a constant reminder to individuals of their HIV status. The availability of long-acting non-orally administered antiretroviral drugs could, therefore, be extremely useful. Cabotegravir (CAB) is a second-generation integrase strand transfer inhibitor, characterized by a relatively high genetic barrier and good antiretroviral potency, which is administrable as a long-acting injectable suspension (LAI CAB).: The authors present and discuss the efficacy and available safety data of LAI CAB, either when co-administered with rilpivirine (RPV; LAI CAB + RPV) for the treatment of HIV infection, or when used as single agent for PrEP.: Cabotegravir has the potential to play a primary role in the treatment and prevention of HIV infection. The future availability of LAI CAB + RPV and LAI CAB may mark the beginning of an era of LAI ART and PrEP, respectively.
: 口服暴露前预防 (PrEP) 和抗逆转录病毒疗法 (ART) 是 HIV 感染预防和治疗的基石。然而，尽管它们具有高效性，但每天服用口服药丸会对长期患者依从性产生负面影响。在某些情况下，它还可能与药物相互作用和胃肠道不良反应有关，并且会不断提醒个人的 HIV 状况。因此，长效非口服给予的抗逆转录病毒药物的可用性可能非常有用。卡博特韦（CAB）是第二代整合酶链转移抑制剂，具有相对较高的遗传屏障和良好的抗逆转录病毒效力，可以作为长效注射混悬剂（LAI CAB）给予。: 作者介绍并讨论了 LAI CAB 的疗效和可用的安全性数据，当与利匹韦林（RPV；LAI CAB + RPV）联合用于治疗 HIV 感染时，或当用作预防 PrEP 的单一药物时：卡博特韦有可能在 HIV 感染的治疗和预防中发挥主要作用。LAI CAB + RPV 和 LAI CAB 的未来可用性可能分别标志着 LAI ART 和 PrEP 时代的开始。
